Goldman Sachs raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $11 from $10 and keeps a Sell rating on the shares. MoonLake reported Q4 and full-year results, with cash providing runway into 2H27 under its Hercules Capital facility, the analyst tells investors in a research note. The company shared updates on its pipeline, though doubts remain about the approvability of sonelokimab, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
- Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
- MoonLake Highlights Positive S-OLARIS Data and Investor Day
- MoonLake announces results from Phase 2 trial of Sonelokimab
- MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target